CARDIOLITE
LOE Approachingtetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate
NDAINJECTIONINJECTABLE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
CARDIOLITE (tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate) is tc99m sestamibi is a cationic tc99m complex which has been found to accumulate in viable myocardial tissue in a manner analogous to that of thallous chloride tl-201. Approved for breast cancer. First approved in 1990.
Drug data last refreshed 5d ago
Mechanism of Action
Tc99m Sestamibi is a cationic Tc99m complex which has been found to accumulate in viable myocardial tissue in a manner analogous to that of thallous chloride Tl-201. Scintigraphic images obtained in humans after the intravenous administration of the drug have been comparable to those obtained with…
Indications (1)
Clinical Trials (3)
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Started Aug 2005
445 enrolled
Kawasaki Disease
CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
Started Jan 2005
74 enrolled
Myocardial Infarction
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
Started Jan 2005
79 enrolled
Kawasaki Disease
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.